Bioda VASOLINE ® Launch Conference of Artificial Blood Vessels Held in Shanghai

Watching focus:
 

The survival rate after 12 months with VASOLINE® is over 95%, and other evaluation measures are no worse than the control group. The safety and efficacy of VASOLINE® have been fully validated through clinical trials, it said. After nearly a decade of hard work by Bioda’s research and development team, VASOLINE® has been approved by the National Medical Products Administration for Class III medical device registration in November 2022. The approval of Vasoline ® means that the first domestically developed and manufactured artificial blood vessel will break the monopoly of similar products in the European and American markets.